Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
Sara A. Hurvitz(University of Washington), Javier Cortés(Villa Maria Hospital), Giuseppe Curigliano(European Institute of Oncology), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Shahid Ashfaque(Daiichi Sankyo (United States)), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Roberto Hegg, Jan‐Willem Henning, Joanne Win Yang Chiu(Queen Mary Hospital), Vinod Ganju(Australasian Leukaemia and Lymphoma Group), William Jacot(Inserm), Wei‐Pang Chung(National Cheng Kung University Hospital), Seock‐Ah Im(Seoul National University), Hiroji Iwata(Nagoya City University), Jillian Cathcart(Daiichi Sankyo (Germany)), José Manuel Pérez-García(MedSIR (Spain)), Yali Liu(Tongji University), Anton Egorov(Daiichi Sankyo (United States)), Sevilay Altıntaş(Antwerp University Hospital), Erika Hamilton(Sarah Cannon)
Cited by 12
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k